Home Tags Cancer

Tag: cancer

Anti-CD22 Monomethyl Auristatin Antibody-drug Conjugate Offers Potential Treatment for Non-Hodgkins Lymphoma

Antibody-drug conjugates (ADCs) are target-specific anticancer agents consisting of cytotoxic drugs covalently linked to a monoclonal antibody. They allow specific targeting of drugs to neoplastic...

Total Antibody Quantification for MMAE-Conjugated Antibody-Drug Conjugates: Impact of Assay Format...

The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody...

The Analytical and Bioanalytical Technologies for Characterizing Antibody-drug Conjugates

Antibody-drug conjugates (ADCs) require multiple assays for analytical and bioanalytical characterization due to their heterogeneous and dynamic nature. These assays can help address questions...

Design and Efficacy of Antibody-drug Conjugates in Oncology

The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody...

Linker Stability Enhances Efficacy of Antibody-SN-38

Results from ongoing studies of two bispecific, hexavalent, antibodies, 1R-(E1)-(E1) and 1R-(15)-(15), for treating breast, pancreatic and other solid cancers, were presented during a...

Monoclonal Antibodies (mAbs), the “Magic Bullets” of Cancer Care, Are Now...

Monoclonal Antibodies (mAbs), once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more advances are on the way,...

Phase III Front-line Trial Planned with Brentuximab Vedotin in Advanced Stage...

Interim results from a phase I clinical trial of brentuximab vedotin(SGN-35, Adcetris™, Seattle Genetics/Millennium: The Takeda Oncology Company) in combination with chemotherapy for the...

Data on Brentuximab Vedotin Highlights Positive Findings and Clinically Meaningful Durations...

Data reported today demonstrating that prolonged treatment with Brentuximab Vedotin (SGN-35; Adcetris™, Seattle Genetics) beyond 16 cycles of therapy was associated with clinically meaningful...

Novel Drugs Breaks Down Barriers – Attacks Breast Cancer Cells from...

Throwing stones at castle walls is one way to attack an enemy, but sneaking inside makes the target much more vulnerable. Researchers at Cedars-Sinai's...

Sanofi-Aventis In-licenses Therapeutic Antibody for the Treatment of Solid Cancers From...

Earlier this month French pharmaceutical giant Sanofi-aventis acquired an exclusive world-wide license to one of Oxford BioTherapeutics’ internal preclinical antibody programs. Sanofi-aventis intends to...